TITLE:
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

CONDITION:
Diabetes Mellitus, Type 2

INTERVENTION:
Placebo 0.04 mL twice daily

SUMMARY:

      The purpose of this study is to evaluate the safety and efficacy of a 28-day regimen of
      exenatide (AC2993), given as a monotherapy to subjects with type 2 diabetes mellitus.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Subject has type 2 diabetes mellitus treated with diet and exercise modification
             alone or in combination with one oral antidiabetic agent for no longer than 4 years.

        Exclusion Criteria:

          -  Subject has a clinically significant history or presence of any of the following
             conditions: (a) Hepatic disease, (b) Renal disease, (c) Central nervous system
             disease, (d) Gastrointestinal disease (e) Pulmonary disease (f) Hematologic disease.

          -  Subject is currently treated with any of the following excluded medications: (a)
             Metformin/sulfonylurea combination therapy (b) Thiazolidinediones (c) Insulin as
             outpatient therapy (d) Regular use of drugs that directly affect gastrointestinal
             motility (e) Regular use of systemic corticosteroids by oral, intravenous (IV), or
             intramuscular (IM) route, or potent, inhaled, intrapulmonary, or intranasal steroids
             known to have a high rate of systemic absorption (f) Regular use of medications with
             addictive potential such as opiates, narcotics and tranquilizers (g) Antineoplastic
             agents (h) Transplantation medications (i) Prescription weight-loss medications.
      
